Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Payables (2024 - 2025)

Evommune (EVMN) has disclosed Payables for 2 consecutive years, with $7.8 million as the latest value for Q4 2025.

  • Quarterly Payables fell 6.15% to $7.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.8 million through Dec 2025, down 6.15% year-over-year, with the annual reading at $7.8 million for FY2025, 6.15% down from the prior year.
  • Payables for Q4 2025 was $7.8 million at Evommune, up from $3.6 million in the prior quarter.
  • The five-year high for Payables was $8.3 million in Q4 2024, with the low at $3.6 million in Q3 2025.